Viva Extends Hong Kong Biotech Fever in City's Hottest 2019 IPO
This article is for subscribers only.
Viva Biotech Holdings bucked a decline across Asia on its trading debut following Hong Kong’s most popular initial public offering this year.
The Shanghai-based company lured retail investors with orders for about 107 times the shares initially available to them, the highest ratio among 2019 offerings above $100 million in the city, data compiled by Bloomberg show. The institutional tranche of the IPO was “significantly oversubscribed,” Viva said in a filing, without providing more details.